Bloomberg Lawreports, “The FDA has opened an extensive review of opioid regulations and is launching a framework aimed at preventing overdose-related deaths nationwide, the agency’s head announced Tuesday.” FDA Commissioner Robert M. Califf said the FDA “has initiated a review into past opioid decisions…’with the intended goal of understanding what revisions are needed to support appropriate use of opioid analgesics.’” Califf “told Bloomberg Law that the FDA plans to announce additional information soon on an external group who will help conduct the agency’s review.” Califf “said there’s ‘not that much the FDA can do directly’ in addressing racial and ethnic disparities in overdose fatality rates, but that ‘there’s a lot that we can do by collaborating with the other agencies’” such as CMS and SAMHSA. Califf added, “Most of what we want to do involves close collaboration with some other entity or often more than one entity. There are literally many things that need to be done, each of which is incremental, but if we could do more of them more quickly, it could have a significant effect.”
From the news release of the American Association for Justice.

